Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16.

Schoentgen N, Marolleau J, Delage F, Coquet JB, Fourcade A, Callerot P, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A.

J Contemp Brachytherapy. 2019 Jun;11(3):195-200. doi: 10.5114/jcb.2019.85793. Epub 2019 Jun 28.

2.

Deep learning in medical image analysis: A third eye for doctors.

Fourcade A, Khonsari RH.

J Stomatol Oral Maxillofac Surg. 2019 Sep;120(4):279-288. doi: 10.1016/j.jormas.2019.06.002. Epub 2019 Jun 26.

PMID:
31254638
3.

Evaluation of the "Quadrella" at 3 years: New index to assess functional and oncological performance specific to prostate brachytherapy.

Coquet JB, Delage F, Fourcade A, Callerot P, Goasduff G, Boussion N, Rousseau B, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A.

Brachytherapy. 2018 Sep - Oct;17(5):782-787. doi: 10.1016/j.brachy.2018.05.007. Epub 2018 Jun 21.

PMID:
29936129
4.

The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer.

Fourcade A, Payrard C, Tissot V, Perrouin-Verbe MA, Demany N, Serey-Effeil S, Callerot P, Coquet JB, Doucet L, Deruelle C, Joulin V, Nonent M, Fournier G, Valeri A.

Scand J Urol. 2018 Jun;52(3):174-179. doi: 10.1080/21681805.2018.1438509. Epub 2018 Feb 20.

PMID:
29463177
5.

Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial.

Gervès-Pinquié C, Daumas-Yatim F, Lalloué B, Girault A, Ferrua M, Fourcade A, Lemare F, Dipalma M, Minvielle E.

BMC Health Serv Res. 2017 Feb 13;17(1):133. doi: 10.1186/s12913-017-2066-x.

6.

Should payment for performance depend on mortality?

Loirat P, Ferrua M, Lalloué B, Fourcade A, Minvielle E.

BMJ. 2016 Jun 22;353:i3429. doi: 10.1136/bmj.i3429. No abstract available.

PMID:
27335102
7.

Évaluation oncologique et fonctionnelle après curiethérapie prostatique a 2ans : Trifecta appliqué à la curiethérapie.

Coquet J, Delage F, Perrouin-Verbe M, Malhaire J, Schoentgen N, Fourcade A, Rousseau B, Thoulouzan M, Callerot P, Fournier G, Valeri A.

Prog Urol. 2015 Nov;25(13):836. doi: 10.1016/j.purol.2015.08.241. French. No abstract available.

PMID:
26544436
8.

Évaluation du « Quadrella » a 2ans : nouvel indice de performance oncologique et fonctionnelle spécifique de la curiethérapie prostatique.

Coquet J, Delage F, Perrouin-Verbe M, Malhaire J, Schoentgen N, Fourcade A, Rousseau B, Thoulouzan M, Callerot P, Fournier G, Valeri A.

Prog Urol. 2015 Nov;25(13):836-7. doi: 10.1016/j.purol.2015.08.242. French. No abstract available.

PMID:
26544435
9.

Rôle des biopsies ciblées utilisant un système d'enregistrement 3D avec fusion élastique écho/IRM chez les hommes ayant une suspicion de cancer prostatique.

Fourcade A, Perrouin-Verbe M, Tissot V, Callerot P, Serey-Eiffel S, Cuvelier G, Coquet J, Doucet L, Delage F, Thoulouzan M, Fournier G, Valéri A.

Prog Urol. 2015 Nov;25(13):832. doi: 10.1016/j.purol.2015.08.230. French. No abstract available.

PMID:
26544424
10.

Comparaison des résultats de prédiction du risque d'envahissement ganglionnaire du score de Roach et des tables de Partin : étude multicentrique.

Moulin M, Fourcade A, Phan Q, Mege J, Valeri A, Mourey E, Fournier G, Cormier L.

Prog Urol. 2014 Nov;24(13):785. doi: 10.1016/j.purol.2014.08.009. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461535
11.

Internet-based technologies to improve cancer care coordination: current use and attitudes among cancer patients.

Girault A, Ferrua M, Lalloué B, Sicotte C, Fourcade A, Yatim F, Hébert G, Di Palma M, Minvielle E.

Eur J Cancer. 2015 Mar;51(4):551-7. doi: 10.1016/j.ejca.2014.12.001. Epub 2015 Feb 4.

PMID:
25661828
12.

[Breast cancer follow-up by primary care physician: patient satisfaction in the Metropolitan Paris region].

Fourcade A, Houzard S, Dubot C, Fourquet A, Fridmann S, Dagousset I.

Bull Cancer. 2012 Oct;99(10):915-25. doi: 10.1684/bdc.2012.1640. French.

13.

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.

Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K.

Eur J Cancer. 2012 Mar;48(5):721-7. doi: 10.1016/j.ejca.2012.01.011. Epub 2012 Feb 6. Review.

PMID:
22317952
14.

Metastatic Medulloblastoma in Childhood: Chang's Classification Revisited.

Dufour C, Beaugrand A, Pizer B, Micheli J, Aubelle MS, Fourcade A, Couanet D, Laplanche A, Kalifa C, Grill J.

Int J Surg Oncol. 2012;2012:245385. doi: 10.1155/2012/245385. Epub 2011 Sep 11.

15.

Barriers to staff adoption of a surgical safety checklist.

Fourcade A, Blache JL, Grenier C, Bourgain JL, Minvielle E.

BMJ Qual Saf. 2012 Mar;21(3):191-7. doi: 10.1136/bmjqs-2011-000094. Epub 2011 Nov 7.

16.

[Assessment of the French surgical checklist: the experience of 17 French cancer centres].

Fourcade A, Minvielle E, Blache JL, Bourgain JL.

Ann Fr Anesth Reanim. 2011 Jun;30(6):495-500. doi: 10.1016/j.annfar.2011.04.001. Epub 2011 May 23. French.

PMID:
21601410
17.

Cortical stimulation of the epileptogenic zone for the treatment of focal motor seizures: an experimental study in the nonhuman primate.

Blauwblomme T, Piallat B, Fourcade A, David O, Chabardès S.

Neurosurgery. 2011 Feb;68(2):482-90; discussion 490. doi: 10.1227/NEU.0b013e3181ff9d14.

PMID:
21135746
18.
19.
20.

Analysis of various sequence-specific triplexes by electron and atomic force microscopies.

Cherny DI, Fourcade A, Svinarchuk F, Nielsen PE, Malvy C, Delain E.

Biophys J. 1998 Feb;74(2 Pt 1):1015-23.

21.

[Complementarity of microscopies in the structural analysis of DNA minicircles associated to protein MC1].

Larquet E, Le Cam E, Fourcade A, Culard F, Furrer P, Delain E.

C R Acad Sci III. 1996 Jun;319(6):461-71. French.

PMID:
8881280
22.

Observation of binding and polymerization of Fur repressor onto operator-containing DNA with electron and atomic force microscopes.

Le Cam E, Frechon D, Barray M, Fourcade A, Delain E.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11816-20.

23.

[Evaluation of hospital care. An experiment at the Public Assistance Hospitals in Paris].

Legrain M, Blum-Boisgard C, Fourcade A, Poisson-Salomon AS, Raphael JC.

Bull Acad Natl Med. 1994 May;178(5):823-30; discussion 831-5. French.

PMID:
7953892
24.

3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.

Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis TJ, Kasahara K, Sasaki Y, Takahashi T, et al.

Cancer Res. 1990 Aug 1;50(15):4698-701.

25.

Effect of doxorubicin on mouse hybridoma B cells: stimulation of immunoglobulin synthesis and secretion.

Teillaud JL, Fourcade A, Huppert J, Fridman WH, Tapiero H.

Cancer Res. 1989 Sep 15;49(18):5123-9.

26.

Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.

Tapiero H, Boulé D, Trincal G, Fourcade A, Lampidis TJ.

Leuk Res. 1988;12(5):411-8.

PMID:
3164087
27.

Interferon inducibility and sensitivity of human teratocarcinoma-derived cell lines.

Ogunkolade W, Canivet M, Pochart F, Fourcade A, Chousterman S, Hovanessian A, Peries J.

J Interferon Res. 1987 Jun;7(3):245-54.

PMID:
2440957
28.

[Role of cell pharmacokinetics in the modulation of modalities in the administration of anthracyclines].

Tapiéro H, Boule D, Trincal G, Fourcade A.

Pathol Biol (Paris). 1987 Jan;35(1):20-6. French.

PMID:
3550608
29.

Effect of verapamil on rhodamine 123 mitochondrial damage in adriamycin resistant cells.

Tapiero H, Sbarbati A, Fourcade A, Cinti S, Lampidis TJ.

Anticancer Res. 1986 Sep-Oct;6(5):1073-6.

PMID:
3800316
30.

Changes in biophysical parameters and in phospholipid composition associated with resistance to doxorubicin.

Tapiero H, Mishal Z, Wioland M, Silber A, Fourcade A, Zwingelstein G.

Anticancer Res. 1986 Jul-Aug;6(4):649-52.

PMID:
3752944
31.

Chromosomal changes associated with resistance to doxorubicin: correlation with tumorigenicity.

Tapiero H, Patet J, Fourcade A, Huppert J.

Anticancer Res. 1986 Mar-Apr;6(2):203-8.

PMID:
3707056
32.

Cytogenetic modifications of Friend leukemia cells resistant to adriamycin.

Patet J, Huppert J, Fourcade A, Tapiero H.

Leuk Res. 1986;10(6):651-8.

PMID:
3713252
33.

Cellular pharmacology of anthracycline resistance and its circumvention.

Tapiero H, Fourcade A, Munck JN, Zwingelstein G, Lampidis TJ.

Drugs Exp Clin Res. 1986;12(1-3):265-73.

PMID:
3460753
34.

Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.

Tapiero H, Munck JN, Fourcade A.

Drugs Exp Clin Res. 1986;12(1-3):257-64.

PMID:
3460752
36.

Cross-resistance to rhodamine 123 in Adriamycin- and daunorubicin-resistant Friend leukemia cell variants.

Tapiero H, Munck JN, Fourcade A, Lampidis TJ.

Cancer Res. 1984 Dec;44(12 Pt 1):5544-9.

37.

Fate of aclacinomycin-A and its metabolites effect on cell growth and macromolecular synthesis.

Fourcade A, Farhi JJ, Bennoun M, Goldschmidt E, Tapiero H.

Biochem Pharmacol. 1983 Jun 15;32(12):1819-24.

PMID:
6576787
38.

The effect of dimethyl sulfoxide on the membrane dynamics and the phospholipid composition of two different cell lines.

Tapiero H, Zwingelstein G, Fourcade A, Portoukalian J.

Ann N Y Acad Sci. 1983;411:383-8. No abstract available.

PMID:
6576720
39.

Effect of human interferon on type D retroviruses multiplication in chronically infected cell lines.

Canivet M, Jouanny C, Fourcade A, Lasneret J, Rhodes-Feuillette A, Peries J.

J Interferon Res. 1983;3(1):53-64.

PMID:
6188793
40.

The effect of dimethylsulfoxide on the lipid composition of inducible and non inducible Friend leukemia cells.

Zwingelstein G, Tapiero H, Portoukalian J, Fourcade A.

Biochem Biophys Res Commun. 1982 Sep 30;108(2):437-46. No abstract available.

PMID:
7150302
41.

Uptake, efflux, and hydrolysis of aclacinomycin A in Friend leukemia cells.

Fourcade A, Farhi JJ, Bennoun M, Tapiero H.

Cancer Res. 1982 May;42(5):1950-4.

42.

[Pelvic hydatid cyst: atypical ultrasonographic findings in one case (author's transl)].

Aimino R, Fourcade A, Ayme Y.

J Radiol. 1982 Mar;63(3):197-9. French.

PMID:
7108846
43.
44.
45.

Changes in phospholipid and fatty acid composition in differentiated Friend leukaemic cells.

Zwingelstein G, Tapiero H, Portoukalian J, Fourcade A.

Biochem Biophys Res Commun. 1981 Jan 30;98(2):349-58. No abstract available.

PMID:
7225103
46.

[Changing relative proportions of apolipoproteins of VLDL in chronic male alcoholics (author's transl)].

Dousset JC, Fourcade A, Lamy JN, Soula G.

Pathol Biol (Paris). 1980 Sep;28(7):453-6. French.

PMID:
6999430
47.

Membrane dynamics of Friend leukaemic cells. II. Changes associated with cell differentiation.

Tapiero H, Fourcade A, Billard C.

Cell Differ. 1980;9(4):211-8.

PMID:
7397778
48.

Membrane dynamics of Friend leukaemic cells. I. Changes associated with cell growth.

Fourcade A, Billard C, Tapiero H.

Cell Differ. 1980;9(4):203-10.

PMID:
7397777
49.

Binding studies of NADPH to NADP-specific L-glutamate dehydrogenase from Saccharomyces cerevisiae.

Venard R, Jallon JM, Fourcade A, Iwatsubo M.

Eur J Biochem. 1975 Sep 15;57(2):371-8.

50.

Supplemental Content

Loading ...
Support Center